Maciej Bryl
Overview
Explore the profile of Maciej Bryl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kowalski D, Zaborowska-Szmit M, Bryl M, Byszek A, Dziedzic D, Jaskiewicz P, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39518907
Molecular testing is recommended in patients with metastatic non-small cell lung cancer (NSCLC), but the extent of its use in Poland is unknown. The aim of the POL-MOL study was...
2.
Reinmuth N, Juan-Vidal O, Kowalski D, Bryl M, Kryzhanivska A, Vicente D, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4055-4067.
PMID: 39017667
Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC). Patients And Methods: Patients with ES-SCLC with progressive disease...
3.
Knetki-Wroblewska M, Dziadziuszko R, Jankowski T, Krawczyk P, Bryl M, Stencel K, et al.
Front Oncol
. 2024 Feb;
14:1341084.
PMID: 38322415
Introduction: Pembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) and the expression of programmed death ligand 1 (PD-L1) in <50% of...
4.
Gabryel P, Skrzypczak P, Roszak M, Campisi A, Zielinska D, Bryl M, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254835
Lymphadenectomy is an essential part of complete surgical operation for non-small cell lung cancer (NSCLC). This retrospective, multicenter cohort study aimed to identify factors that influence the lymphadenectomy quality. Data...
5.
Rudin C, Liu S, Soo R, Lu S, Hong M, Lee J, et al.
J Clin Oncol
. 2023 Nov;
42(3):324-335.
PMID: 37976444
Purpose: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung...
6.
Grodzka A, Knopik-Skrocka A, Kowalska K, Kurzawa P, Krzyzaniak M, Stencel K, et al.
EXCLI J
. 2023 Jun;
22:415-432.
PMID: 37346803
Lung cancer is the leading cause of cancer death all over the world. The majority (80-85 %) of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Within...
7.
Pluzanski A, Bryl M, Chmielewska I, Czyzewicz G, Luboch-Kowal J, Wrona A, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900371
Non-small-cell lung cancer (NSCLC) represents 85% of new cases of lung cancer. Over the past two decades, treatment of patients with NSCLC has evolved from the empiric use of chemotherapy...
8.
Siemiatkowska A, Bryl M, Kosicka-Noworzyn K, Tvrdon J, Golda-Gocka I, Glowka F
Cancer Immunol Immunother
. 2023 Jan;
72(6):1853-1863.
PMID: 36688998
Background: Immunotherapy has changed the paradigm of treating non-small cell lung cancer (NSCLC). But, selecting patients who will achieve long-term benefits from treatment remains unsatisfactory. Here, we investigated the possible...
9.
de Castro Jr G, Rizvi N, Schmid P, Syrigos K, Martin C, Yamamoto N, et al.
J Thorac Oncol
. 2022 Oct;
18(1):106-119.
PMID: 36240972
Introduction: NEPTUNE, a phase 3, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC). Methods: Eligible patients with EGFR and ALK wild-type mNSCLC were randomized (1:1)...
10.
Konkol M, Bryl M, Fechner M, Matuszewski K, Sniatala P, Milecki P
J Pers Med
. 2022 Mar;
12(3).
PMID: 35330484
Radiation-induced lung injury remains a significant toxicity in thoracic radiotherapy. Because a precise diagnosis is difficult and commonly used assessment scales are unclear and subjective, there is a need to...